September 19, 2011

Pacific Biosciences Partners with Cycle Computing to Bring SMRT DNA Analysis to the Cloud

MENLO PARK, Calif.–(BUSINESS WIRE)–

Pacific Biosciences of California, Inc. (NASDAQ: PACB), provider of

Single Molecule Real Time (SMRT®) sequencing products,

announced today that the company has partnered with Cycle Computing to

optimize the PacBio RS SMRT Analysis software for the cloud.

Preliminary demonstrations of the solution will be presented this week

by Cycle Computing at the Bio-IT World Cloud Computing conference on

September 20 in La Jolla, California and the Amazon Web Services

Genomics Event on September 22 in Seattle, Washington.

The cloud-based version of the SMRT Analysis software suite is designed

to provide dynamic, high performance computing that scales to meet the

data analysis needs for SMRT sequencing and supports a workflow that

includes sample preparation, sequencing and completed data analysis in

less than one day. A beta version of the solution is expected to be

available with the next major PacBio RS upgrade, currently

scheduled for the end of 2011.

“Analysis of long, single molecule, real-time sequencing reads from

unamplified samples without the need to maintain complex and expensive

hardware and software will offer customers more flexibility to realize

the potential of the PacBio RS,” said Edwin Hauw, Director of

Software Product Management for Pacific Biosciences. “By leveraging

Cycle Computing’s expertise in building scalable, high performance cloud

computing applications our goal is to provide the best balance of

performance and convenience for customers.”

For more information about PacBio’s SMRT Analysis software, see the

PacBio DevNet site at https://www.pacbiodevnet.com.

For more information about Pacific Biosciences, please visit www.pacificbiosciences.com.

You can also follow the company on Twitter: www.twitter.com/pacbio.

About Pacific Biosciences

Pacific Biosciences’ mission is to transform the way humankind acquires,

processes and interprets data from living systems through the design,

development and commercialization of innovative tools for biological

research. The company has developed a novel approach to studying the

synthesis and regulation of DNA, RNA and proteins. Combining recent

advances in nanofabrication, biochemistry, molecular biology, surface

chemistry and optics, Pacific Biosciences has created a powerful

technology platform called single molecule, real-time, or SMRT®,

technology. SMRT technology enables real-time analysis of biomolecules

with single molecule resolution, which has the potential to transform

the understanding of biological systems by providing a window into these

systems that has not previously been open for scientific study.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking

statements may contain words such as “believe,” “may,” “estimate,”

“anticipate,” “continue,” “intend,” “expect,” “plan,” the negative of

these terms, or other similar expressions, and include the assumptions

that underlie such statements. Such statements include, but are not

limited to, statements regarding the Company’s SMRT technology. These

statements are subject to known and unknown risks and uncertainties that

could cause actual results to differ materially from those expressed or

implied by such statements, including but not limited to risks discussed

from time to time in documents Pacific Biosciences of California, Inc.

has filed with the Securities and Exchange Commission, including the

risks identified under the section captioned “Risk Factors” in its

recently filed Quarterly Report on Form 10-Q. All forward-looking

statements are based on estimates, projections and assumptions as of the

date hereof. Pacific Biosciences undertakes no obligation to update any

forward-looking statements.

For Pacific Biosciences
Nicole Litchfield, 415-793-6468 (Media)
nicole@bioscribe.com
or
Pacific

Biosciences
Trevin Rard, 650-521-8450 (Investors)
ir@pacificbiosciences.com
or
For

Cycle Computing
Articulate Communications Inc.
Laura Anderson,

212-255-0080, ext. 11 (Media)
landerson@articulatecomms.com

Source: Pacific Biosciences of California, Inc.

News Provided by Acquire Media

Talk with an expert

If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.